Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.520
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
October 11, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Chief Financial Officer Succession
September 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
May 30, 2023
Via
Investor Brand Network
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
July 05, 2023
Via
Investor Brand Network
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
July 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
June 20, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
May 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.